Innovation is Coming | Fortis Life Sciences

Innovation is Coming. Explore Early-Access Opportunities.

Bethyl will soon be advancing its custom antibody discovery portfolio with somatically matured bovine ultra-long CDRH3 technology. This platform offers access to isolated knob domains, among the smallest known antibody fragments capable of binding independently.

Discovery shaped by the immune response:

Harness bovine adaptive affinity maturation to identify target-specific, high-affinity candidates.

Compact domains. Independent binding:

Explore selected knob domains that retain antigen recognition as standalone fragments.

Multiple specificities.
One construct:

Combine or graft knob domains to explore coordinated targeting of multiple antigens.

Target deliberately. It’s someone’s tomorrow.